Akshay Desai, MD
Cardiovascular Disease · Boston, MANPI 1063478311
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $281,997 of the $346,622 with a category attached, or 81.4%. It is spread thinly across 25 manufacturers, the largest accounting for just 18.0%. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $1468.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$63K
- Abbott$55K
- Novartis Pharma AG$37K
- Regeneron$29K
- Novartis$23K
- AstraZeneca$22K
- plus $117K from 19 others
Across 52 payments — averaging $137,261 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$5M
- Astrazeneca UK Limited$2M
- Pfizer$58K
- Alnylam Pharmaceuticals Inc.$42K
- Bayer$5K
- Medtronic$1K
What the payments were for
- Consulting fees$281,99781%
- Speaking & faculty fees$38,41311%
- Travel & lodging$21,1296%
- Food & beverage$5,0831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 23 | $62,529 |
| Abbott | 83 | $55,256 |
| Novartis Pharma AG | 16 | $37,326 |
| Regeneron | 34 | $29,380 |
| Novartis | 9 | $23,335 |
| AstraZeneca | 7 | $21,953 |
| Astrazeneca UK Limited | 6 | $18,394 |
| Merck | 12 | $15,030 |
| Pfizer | 1 | $13,400 |
| GSK | 5 | $12,100 |
| Bayer | 5 | $10,005 |
| Anumana, Inc. | 1 | $8,000 |
| Amgen | 3 | $6,488 |
| Endotronix, Inc. | 3 | $6,119 |
| Boston Scientific | 12 | $5,982 |
| Roche Diagnostics International Ltd | 1 | $4,550 |
| Scpharmaceuticals Inc. | 2 | $4,000 |
| Medtronic | 3 | $3,629 |
| F. Hoffmann-la Roche AG | 2 | $3,308 |
| Novo Nordisk | 1 | $3,000 |
| Dr.reddy's Laboratories,inc. | 1 | $1,500 |
| Irhythm Technologies, Inc. | 1 | $750 |
| Volta Medical Inc | 1 | $500 |
| Astrazeneca AB | 3 | $70 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$33,830
- CardioMEMS HF System$24,291
- CARDIOMEMS$17,537
- LCZ696B_ENTRESTO_CARDIOVASCULAR$17,107
- Kerendia$9,968
- HeartMate$8,671
- ECG-AI LEF$8,000
- LCZ696D_ENTRESTO_CARDIOVASCULAR$7,862
- FARXIGA$7,500
- CORDELLA PULMONARY ARTERY PRESSURE SENSOR$5,750
- FUROSCIX$4,000
- GENERAL - THERAPIES$2,738
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,966
- HeartMate PHP$1,313
- CLINICAL TRIAL PRODUCT$1,250
- ZIO XT Patch$750
- Zio monitor$750
- VERQUVO$750
- VX1$500
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$294
How this compares
$346,622 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 27 | $645,018 |
| EntrestoSacubitril/Valsartan | 191 | $278,114 |
| EliquisApixaban | 151 | $201,988 |
| JardianceEmpagliflozin | 134 | $172,693 |
| FarxigaDapagliflozin Propanediol | 106 | $149,237 |
| XareltoRivaroxaban | 41 | $49,680 |
| Repatha SureclickEvolocumab | 17 | $11,993 |
| OzempicSemaglutide | 11 | $9,313 |
| Metoprolol Succinate | 311 | $8,002 |
| Repatha SyringeEvolocumab | 12 | $6,756 |
| DapagliflozinDapagliflozin Propanediol | 13 | $6,755 |
| Rosuvastatin Calcium | 101 | $4,375 |
| Atorvastatin Calcium | 257 | $4,287 |
| Ezetimibe | 60 | $3,162 |
| Torsemide | 94 | $2,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $13,400 | $847,006178 claims |
| NovartisEntresto | $23,335 | $278,114191 claims |
| AstraZenecaFarxiga | $21,953 | $149,237106 claims |
| Novo NordiskOzempic | $3,000 | $9,31311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.